GID.AX - GI Dynamics, Inc.

ASX - ASX Delayed Price. Currency in AUD
0.019
-0.001 (-5.00%)
At close: 11:48AM AEDT
Stock chart is not supported by your current browser
Previous close0.020
Open0.019
Bid0.000 x 0
Ask0.000 x 0
Day's range0.019 - 0.019
52-week range0.018 - 0.050
Volume140,000
Avg. volume79,074
Market cap14.566M
Beta (3Y Monthly)3.04
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
Press Releases
  • Business Wire17 days ago

    GI Dynamics Announces Selection of New Notified Body

    GI Dynamics, Inc. (GID.AX), a medical device company that is developing EndoBarrier for patients with type 2 diabetes and obesity, is pleased to announce the selection of Intertek as the company’s notified body to continue working toward attaining the EndoBarrier CE Mark. GI Dynamics selected Intertek for its medical device expertise and availability to support the clinical and regulatory requirements of EndoBarrier and GI Dynamics.

  • Business Wirelast month

    GI Dynamics Announces AUD $6.9m Private Placement to be Completed in Two Tranches

    GI Dynamics, Inc. (GID.AX), a medical device company that is developing EndoBarrier for patients diagnosed with type 2 diabetes and obesity, is pleased to announce it has received binding commitments for a private placement of 347,222,250 CHESS Depositary Interests (CDIs) of the Company (representing 6,944,445 shares of common stock) at an issue price of AUD $0.020 per CDI to certain sophisticated and professional investors in Australia, the United States, and the United Kingdom to raise approximately AUD $6.944 million (representing approximately USD $5 million using an exchange rate of USD $0.72 per AUD) (Placement). The issue of CDIs under the Placement will occur in two tranches.

  • Business Wire2 months ago

    GI Dynamics Announces FDA Approval for EndoBarrier Pivotal Trial

    GI Dynamics Inc. (GID.AX), a medical device company that is developing EndoBarrier for patients diagnosed with type 2 diabetes and obesity, is pleased to announce it has received approval of an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in a pivotal trial evaluating the safety and efficacy of EndoBarrier in the United States pending Institutional Review Board (IRB) approval.

  • Business Wire5 months ago

    EndoBarrier Meta-Analysis Published in Diabetes Care Journal

    GI Dynamics® Inc. , a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the meta-analysis, “Effects of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Type 2 Diabetic Patients with Obesity: A Meta-analysis with Secondary Analysis on Weight Loss and Hormonal Changes,” by Pichamol Jirapinyo, MD, of Brigham and Women’s ...

  • Business Wire9 months ago

    GI Dynamics Announces AUD $2.05m Private Placement and Close of First Tranche of AUD ~$1m

    GI Dynamics®, Inc. , a medical device company that is developing EndoBarrier® is pleased to announce that it has received binding commitments for a private placement of 58,780,619 CHESS Depositary Interests of the Company at an issue price of AUD $0.035 per CDI to sophisticated and professional investors in Australia, the United States, and the United Kingdom to raise approximately AUD $2.05 million ...

  • Business Wire9 months ago

    GI Dynamics, Inc. Provides 2017 Review and 2018 Business Outlook

    GI Dynamics®, Inc. , a medical device company that is developing EndoBarrier® provides shareholders with a review of 2017 activities and its 2018 business outlook.

  • Business Wire11 months ago

    GI Dynamics Announces Change to Board of Directors

    GI Dynamics®, Inc. , a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America, announces today that the board of directors has received the resignation of GI Dynamics non-executive directors Anne Keating and Graham Bradley.

  • Business Wire11 months ago

    GI Dynamics to Provide Corporate Update and 2017 Third Quarter Results

    GI Dynamics® Inc. , a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces it will provide a corporate update and discuss 2017 third quarter results to investors.

  • Business Wire11 months ago

    GI Dynamics Receives CE Certificate of Conformity Withdrawal Notice for EndoBarrier

    GI Dynamics®, Inc. , a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America has received notification from its notified body SGS United Kingdom, Limited that SGS will withdraw the CE Certificate of Conformity for EndoBarrier effective 12 November 2017.